Gene Therapy for Dravet Syndrome - A Rare Epilepsy – Moran Rubinstein & Eric Kremer 1/2
Scientists Moran Rubinstein from Tel Aviv University and Eric Kremer from INSERM speak of their exciting project on gene therapy for the rare genetic epilepsy Dravet Syndrome. They talk about their research processes, outcomes and treatment side-effects, safety, the patent, and the next steps with pharma. This is just part 1 of 2 regarding their exciting work!
-
Moran Rubinstein is an Asst. Prof. and the PI of the Rubinstein Lab at Tel Aviv University in Israel. Moran’s projects focus on three forms of developmental epileptic encephalopathy: Dravet Syndrome, GRIN2D, and CHD2, where the neuronal and molecular basis of visual system abnormalities in severe epilepsy and autism are studied.
Eric Kremer is the Director of Research at the French National Institute of Health and Medical Research (INSERM) and Director of a research lab at the Institut de Génétique Moléculaire de Montpellier (IGMM) in France. His lab develops and studies viral tools for gene therapy of neurological and other diseases.
Special thanks
Moran and Eric give thanks to their project team members:Saja Fadial, Bertrand Beucher, Iria González-Dopeso Reyes, Anat Mavashov, Marina Brusel, and Karen Anderson.
They would also like to thank other members of their team: Yael Almog, Shir Quinn, Mor Yam, Shaked Turk, and Jolan Nasir.
-
Moran:
Relevant paper | Dravet Syndrome Foundation | Twitter | LinkedIn | Lab | Tel Aviv University - profile | ResearchGate | Orcid | Loop | PubMed | Google Scholar | Cell | AES | RAMOT | CRIS | Scorpus
Eric:
Relevant paper | Dravet Syndrome Foundation | Lab | IGMM – Institut de Génétique Moléculaire de Montpellier | ResearchGate | PubMed | Orcid | Cell | AES | Loop | Google Scholar
-
Join me and share on social
Other episodes:
Help people in Ukraine with epilepsy
Helplines, email address, and website for Ukrainians seeking anti-seizure medications.